AgomAb Therapeutics NV (AGMB) stock
AGMBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$5.92−0.05 (-0.84%)
Close on Nov 17, 2026Market cap $148.00KP/E –Yield –
AgomAb Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
For fiscal 2025 it was €48.88M, up 24.3% from the year before.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | €48.88M | +24.3% |
| FY2024 | Dec 31, 2024 | €39.31M | +49.4% |
| FY2023 | Dec 31, 2023 | €26.31M | – |
See a number that looks wrong?